Welcome to our dedicated page for OMEROS SEC filings (Ticker: OMER), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OMEROS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OMEROS's regulatory disclosures and financial reporting.
Omeros Corporation disclosed preliminary year-end liquidity figures following an investor call. The company reported that at December 31, 2025, it had approximately $171.5 million in cash and short-term investments available for operations. This amount is described as preliminary and unaudited and may change after the company completes its customary financial closing procedures and adjustments.
The disclosure is provided under a current report and is specifically designated as “furnished” rather than “filed,” meaning it is not subject to certain liability provisions and will not automatically be incorporated into other securities filings.
Omeros Corporation reported that the U.S. Food and Drug Administration has approved YARTEMLEA® (narsoplimab-wuug) to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a serious and often fatal complication of stem-cell transplantation linked to activation of the lectin pathway of complement. The company issued a revised press release on December 24, 2025 to update the date of its YARTEMLEA approval-related conference call and to add supplemental information about the experts quoted, with no other changes to the release.
Omeros Corporation launched an at-the-market offering of up to $150,000,000 of common stock under a Controlled Equity Offering agreement with Cantor Fitzgerald as sales agent. Shares may be sold from time to time on Nasdaq or through negotiated transactions, with Cantor earning up to 3.0% of the gross sales price per share.
Proceeds will be used for general corporate purposes, including clinical and pre-clinical development, commercialization activities, working capital, potential debt repayment, acquisitions or investments, and other capital expenditures. As context, based on the November 13, 2025 closing price of $6.28, the company illustrates a maximum of 23,885,350 shares. Omeros reported 70,073,622 shares outstanding as of September 30, 2025, and provides an example showing 93,958,972 shares if the full amount were sold at that price. Estimated offering expenses are approximately $300,000.
Omeros Corporation reported a wider third‑quarter net loss while managing liquidity and advancing key transactions. For Q3 2025, net loss was $30.9 million, including a $21.2 million loss from continuing operations and a $9.7 million loss from discontinued operations. Operating costs eased year over year, with R&D $16.0 million (down from $24.1 million) and SG&A $10.4 million (down from $11.3 million).
As of September 30, 2025, cash, cash equivalents, and short‑term investments totaled $36.1 million, and cash used in operations for the nine months was $76.3 million. Shareholders’ deficit was $220.5 million. The company disclosed substantial doubt about its ability to continue as a going concern absent additional financing, asset sales, or closing its pending transaction.
On October 10, 2025, Omeros signed an Asset Purchase and License Agreement with Novo Nordisk, eligible for $340.0 million in upfront and near‑term payments, including $240.0 million at closing, plus up to $410.0 million in development/approval milestones, up to $1.3 billion in sales milestones, and tiered royalties. The transaction is expected to close in Q4 2025. The FDA target action date for narsoplimab in TA‑TMA was extended to December 26, 2025; an EU opinion is expected mid‑2026.
Omeros Corporation filed a current report to furnish its latest quarterly results. The company issued a press release on November 13, 2025, covering financial results for the three and nine months ended September 30, 2025, and attached this release as Exhibit 99.1.
The report clarifies that the press release and related information are being furnished, not filed, under securities laws, limiting associated liability and preventing automatic incorporation into other regulatory filings unless specifically included.
Omeros entered an Asset Purchase and License Agreement with Novo Nordisk granting exclusive global rights to develop and commercialize zaltenibart (OMS906) and related compounds. Omeros is eligible for up to $2.1 billion, including an upfront cash payment of $240.0 million at closing, up to $510 million in development and approval milestones, and up to $1.3 billion in sales-based milestones. The agreement also provides for tiered royalties on annual net sales at percentage rates ranging from high single digit to high teens.
The transaction is subject to customary conditions, including HSR waiting period expiration or termination, accuracy of representations, covenant compliance, and the absence of a material adverse effect, and is expected to close in the fourth quarter of 2025. At closing, a portion of the $240.0 million will repay the $67.1 million outstanding term loan under the 2024 Credit Agreement, along with related prepayment premiums and accrued interest, releasing all liens and covenants. Omeros retains certain MASP‑3 program rights, including small‑molecule development, and will provide transition services reimbursed by Novo Nordisk.
Omeros (OMER) reported an insider transaction by Chairman, CEO & President Gregory A. Demopulos. On October 13, 2025, he made bona fide gifts of common stock—300,000 shares each—to two irrevocable trusts established for the benefit of his minor children at a reported price of $0 (transaction code G).
Following these gifts, he directly holds 1,426,986 shares. Indirect holdings include 300,000 shares in each child trust and 123,945 shares held by his spouse. He disclaims beneficial ownership of the trust and spouse shares except to the extent of any pecuniary interest.
Omeros (OMER) has entered into a registered direct offering of 5,365,853 common shares at $4.10, a 14% premium to the 24-Jul-25 close ($3.59). Gross proceeds total $22.0 million; after the 6% placement fee to D. Boral Capital ($1.32 million) and other expenses, net cash is expected at roughly $20.3 million.
The raise increases shares outstanding from 61.8 million to 67.1 million (≈8.7% dilution) and lifts available cash from ≈$26 million (18-Jul-25) to >$45 million, funding general corporate uses, clinical and pre-clinical pipeline work and working capital. Management retains broad spending discretion.
Key pipeline points: FDA’s BLA for lead MASP-2 antibody narsoplimab in TA-TMA now carries a 26-Dec-25 PDUFA date; EMA review is ongoing with an opinion expected mid-2026. The company is also advancing MASP-3 inhibitor zaltenibart (PNH, C3G) and PDE7 program OMS527 (cocaine use disorder). Omeros is negotiating a potential multi-billion-dollar asset deal that could retire its $67.1 million term loan and part of its 2026 notes.
Despite the premium pricing, the offer adds to a $(193 million) adjusted tangible book deficit and follows an auditor going-concern warning. Investors face immediate dilution of $7.15 per share (net tangible book value basis) and future overhang from 19.6 million outstanding options and convertible notes.